Dispelling the myths around cancer care delivery: It's not all about costs

Journal of Cancer Policy

Volumn 2, Issue 1, 2014, Pages 22-29

  Uyl de Groot, Carin A ^a   de Vries, Elisabeth G E ^b   Verweij, Jaap ^c   Sullivan, Richard ^d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adoption; Cancer; Cancer drugs; Clinical relevance; Cost; Diffusion; Dynamic process; Guidelines; Innovation; Outcome

Indexed keywords

CANCER CENTER; CANCER MORTALITY; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LITERATURE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 84897110104     PISSN: None     EISSN: 22135383     Source Type: Journal    
DOI: 10.1016/j.jcpo.2014.01.001     Document Type: Review

References (38)

1. Philipson T., Eber M., Lakdawalla D.N., Corral M., Conti R., Goldman P. An analysis of whether higher health care spending in the United States versus Europe is 'Worth It' in the case of cancer. Health Aff 2012, 31:4667-4675.
2. Sun E., Jena A., Lakdawalla D., Reyes C., Philipson T., Goldman D. An economic evaluation of the war on cancer 2009, National Bureau of Economic Research, Cambridge, MA, Contract No: 15574.
3. Luengo-Fernandez R., Leal J., Gray A., Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013, 14:1165-1174.
4. [accessed 05.01.14]. http://data.worldbank.org/news/world-development-indicators-2012-now-available.
5. [accessed 05.01.14]. http://stats.oecd.org/.
6. Health at a glance 2012, OECD Publishing, Europe, [accessed 05.01.14]. http://dx.doi.org/10.1787/9789264183896-en.
7. Porter M.E. A Strategy for health care reform - toward a value-based system. N Engl J Med 2009, 361:109-112.
8. De Vries E., Karim-Kos H.E., Janssen-Heijnen M.L.G., Soerjomataram I., Kiemeney L.A., Coebergh J.W. Explanations for worsening cancer survival. Nat Rev Clin Oncol 2010, 7:60-63.
9. Tao L., Wang R., Gao Y.T., Yuan J.M. Impact of postdiagnosis smoking on long-term survival of cancer patients: the Shanghai cohort study. Cancer Epidemiol Biomarkers Prev 2013, 22:2404-2411.
10. Rheingold S.R., Neugut A.I., Meadows A.T., Rheingold S.R., Neugut A.I., Uldrick T., Meadows A.T. Treatment-related secondary cancers. Holland-Frei cancer medicine 2009, 1915-1920. People's Medical Publishing House, Shelton. 8th ed. W.K. Hong, R.C. Bast, W.N. Hait, D.W. Kufe, R.E. Pollack, R.R. Weichselbaum, J.F. Holland, E.F. Frei (Eds.).
11. Oeffinger K.C., Baxi S.S., Novetsky Friedman D., Moskowitz C.S. Solid tumor second primary neoplasms: who is at risk, what can we do?. Semin Oncol 2013, 40:676-689.
12. Lewison G., Tootell S., Roe P., Sullivan R. How do the media report cancer research? A study of the UK's BBC website. Br J Cancer 2008, 99:569-576.
13. Raphael C., Ahrens J., Fowler N. Financing end-of-life care in the USA. J R Soc Med 2001, 94:458-461.
14. Silvia Francisci S., Stefano Guzzinati S., Maura Mezzetti M., Emanuele C., Francesco G., Guido M., et al. Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. BMC Cancer 2013, 13:329.
15. Pfister D.G. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. J Clin Oncol 2013, 31:3487-3489.
16. Experts in Chronic Myeloid Leukemia The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121:4439-4442.
17. The Health Foundation Summit report: leading the way to shared decision making 2012, [accessed 05.01.14]. http://www.health.org.uk/public/cms/75/76/313/3293/Leading%20the%20way%20to%20shared%20decision%20making.pdf%3FrealName=RmwIPj.pdf.
18. Rogers E.M. Diffusion of innovations 1962, The Free Press, New York.
19. Berwick D.M. Disseminating innovation in health care. JAMA 2003, 289:1969-1975.
20. Blommestein H.M., Franken M.G., Verelst S.G.R., van Agthoven M., Huijgens P.C., Uyl-de Groot C.A. Access to expensive cancer drugs in Dutch daily practice: should we be concerned?. Neth J Med 2014, [in press].
21. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
22. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352(24):2487-2498.
23. [accessed 10.01.14]. http://www.fda.gov/NewsEvents/Newsroom/ucm280585.htm.
24. Purushotham A., Bains S., Lewison G., Szmukler G., Sullivan R. Cancer and mental health - a clinical and research unmet need. Ann Oncol 2013, 24:2274-2278.
25. Reames B.N., Krell R.W., Ponto S.N., Wong S.L. Critical evaluation of oncology clinical practice guidelines. J Clin Oncol 2013, 31:2563-2568.
26. http://www.choosingwisely.org/doctor-patient-lists/american-society-of-clinical-oncology/.
27. Ellis L.M., Bernstein D., Voest E., Berlin J., Sargent D., Cortazar P., et al. Defining clinically meaningful outcomes: ASCO Recommendations to raise the bar for clinical trials. Am Soc Clin Oncol 2014, http://www.asco.org/sites/www.asco.org/files/asco_meaningful_outcomes_draft_for_website_-_05_13_13_0.pdf.
28. Sobrero A., Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009, 27:5868-5873.
29. NVMO Systematische beoordeling van oncologische middelen. Medische Oncologie 2012, 1:26-29. [In Dutch].
30. Franken M.G., van Gils C.W., Gaultney J.G., Delwel G.O., Goettsch W., Huijgens P.C., et al. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands. Eur J Cancer 2013, 49:8-16.
31. van Gils C.W., de Groot S., Redekop W.K., Koopman M., Punt C.J., Uyl-de Groot C.A. Real-world cost-effectiveness of oxaliplatin in stage iii colon cancer: a synthesis of clinical trial and daily practice evidence. Pharmacoeconomics 2013, 31:703-718.
32. Ilgen D.R., Hollenbeck J.R., Johnson M., Jundt D. Teams in organizations: from input-process-output models to IMOI models. Rev Psychol 2005, 56:517-543.
33. [accessed 10.01.14]. http://qopi.asco.org/References.Htm.
34. Louwman W.J., Aarts M.J., Houterman S., van Lenthe F.J., Coebergh J.W., Janssen-Heijnen M.L. A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer 2010, 103:1742-1748.
35. Oshima E., Emanuel E.J. Shared decision making to improve care and reduce costs. N Engl J Med 2013, 368:6-8.
36. Wennberg J.E., O'Connor A.M., Collins E.D., Weinstein J.N. Extending the P4P agenda. Part 1. How Medicare can improve patient decision making and reduce unnecessary care. Health Aff (Millwood) 2007, 26:1564-1574.
37. Katz S.J., Hawley S. The value of sharing treatment decision making with patients: expecting too much?. JAMA 2013, 310:1559-1560.
38. Helwick C. Sharing treatment decision-making with patients: where's the evidence of value. JAMA 2013, 310:1559-1560.